Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.68 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9421282 | 0.93 | PTGS1 (0.74) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL11867356 | 0.91 | PTGS1 (0.63) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL2015568 | 0.88 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL10797351 | 0.87 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL680902 | 0.87 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL9817253 | 0.87 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL1503471 | 0.86 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL10490007 | 0.86 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione Ethyl Ester SCHEMBL7530345 | 0.86 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1 | |
| Glutathione Ethyl Ester SCHEMBL680361 | 0.86 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370144-A1 | GLUTAHTIONE C4 AGAINST AIRWAY AFFECTIONS | Redox-co S.r.l. (IT) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023285984-A1 | GLUTAHTIONE C4 AGAINST AIRWAY AFFECTIONS | REDOX-CO S.R.L. (IT) | 2023-01-19 | — | — | WO | disclosed |
| US-20120165248-A1 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases | FIRST S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| EP-1701973-B1 | GLUTATHIONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VIRAL DISEASES | FIRST SOCIETA A RESPONSABILITA (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20070270349-A1 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases | FIRST S.R.L. (IT) | 2007-11-22 | — | — | US | disclosed |
| EP-1701973-A1 | GLUTATHIONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VIRAL DISEASES | Benatti, Umberto (IT) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063795-A1 | GLUTATHIONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VIRAL DISEASES | BENATTI UMBERTO (IT) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165248-A1 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases | GSS, GSR, GPX1 | PTGS1 86/4885GSTK1 5/4885GLO1 30/4885 |
| US-20070270349-A1 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases | GSS, GSR, GPX1 | PTGS1 96/4885GSTK1 5/4885GLO1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.